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Abstract: Cancer stem cells (CSCs) are a subpopulation of cells that can initiate, self-renew, and
sustain tumor growth. CSCs are responsible for tumor metastasis, recurrence, and drug resistance in
cancer therapy. CSCs reside within a niche maintained by multiple unique factors in the microenvironment. These factors include hypoxia, excessive levels of angiogenesis, a change of mitochondrial
activity from aerobic aspiration to aerobic glycolysis, an upregulated expression of CSC biomarkers
and stem cell signaling, and an elevated synthesis of the cytochromes P450 family of enzymes responsible for drug clearance. Antibodies and ligands targeting the unique factors that maintain the
niche are utilized for the delivery of anticancer therapeutics to CSCs. In this regard, nanomaterials,
specifically nanoparticles (NPs), are extremely useful as carriers for the delivery of anticancer agents
to CSCs. This review covers the biology of CSCs and advances in the design and synthesis of NPs as
a carrier in targeting cancer drugs to the CSC subpopulation of cancer cells. This review includes
the development of synthetic and natural polymeric NPs, lipid NPs, inorganic NPs, self-assembling
protein NPs, antibody-drug conjugates, and extracellular nanovesicles for CSC targeting.
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1. Introduction
According to a report by the World Health Organization (WHO), cancer is recognized
as the second leading cause of death in the world, with over 18 million cases and close to
10 million cancer-related mortalities in 2018 [1]. Due to the rapid pace of industrialization,
it is anticipated that cancer mortality rates will nearly double by 2040 [2]. Conventional
cancer therapies, such as surgical resection of tumor, radiotherapy, and chemotherapy,
not only destroy tumor cells, but they also harm healthy cells in cancer patients, leading
to many undesired side effects, such as a loss of appetite, anemia, internal bleeding, and
fatigue [3]. Among the cells within a tumor, there is a small subpopulation, typically less
than one percent, that are highly resistant to conventional therapies. These cells are called
cancer stem cells (CSCs) or cancer-initiating cells (CICs). The existence of CSCs, with their
unique properties and cellular markers, has been reported in a broad range of cancers,
including breast [4], colon [5], lung [6], prostate [7], liver [8], melanoma [9], leukemia [10],
head and neck [11], ovarian [12], pancreatic [13], and brain tumors [14]. CSCs provide a
unique strategy to treat patients with highly resistant, metastatic, and malignant cancers. To
this end, the multidisciplinary field of nanotechnology promises new approaches to cancer
treatment by targeting therapeutics to CSCs, the most resistant cells in the tumor tissue,
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thus potentially eliminating the undesired effects of therapeutics [15]. Recent years have
witnessed the development of various organic and inorganic nanocarriers, with different
sizes and shapes, as promising tools for CSC targeted therapies [16]. This review aims to
summarize new trends and developments in various nanomaterials, including organic and
inorganic nanoparticles (NPs), for targeting CSCs.
2. Cancer Stem Cell Biology
Cancer is defined as a biological condition in which some cells in a tissue of a bodily
organ undergo an uncontrolled division and growth [3]. In 1997, Bonnet and Dick realized
that a small subpopulation of these abnormal cells have different properties from those of
bulk tumor cells. After isolation, they demonstrated that this small population of leukemiainitiating cells have features similar to stem cells and announced the concept of cancer
stem cells (CSCs) [17]. Later studies in various types of solid tumors revealed the existence
of CSCs in almost all cancer types, from brain to colon and prostate. The majority of
cells in bulk tumors are normal and non-tumorigenic and behave like background cells
with no special privileges, compared to CSCs [18,19]. CSCs can be compared with normal
stem cells in different tissues of the body. Normal stem cells, when activated, undergo
an asymmetric cell division (ACD) to self-renew and give rise to a distinct population of
progenitors. These progenitors then undergo a symmetric cell division (SCD) to clonally
expand and replenish lost cells [20]. CSCs in some ways act like normal stem cells for
the tumor tissue. Evidence shows that normal cancer cells exhibit plasticity and undergo
dedifferentiation to a stem-like state, like the epithelial-to-mesenchymal transition (EMT).
These dedifferentiated cells acquire properties of stemness and become more invasive and
metastatic. A key characteristic of CSCs is their ability to evade the attack by immune cells,
like natural killer (NK) and CD8-positive cytotoxic T cells, through the active recruitment
of immune suppression cells, expression of immune suppressive factors, or induction of
apoptosis in T lymphocytes [21]. Other important features of CSCs include:

•
•
•
•
•
•
•

Self-renewal and DNA repair: this extraordinary property of CSCs causes tumor
relapse and radiation-resistance in tumors [22].
Differentiation into multiple cell types: the pluripotency of CSCs causes heterogeneity
in solid tumors [23].
Ionizing radiation: this feature makes CSCs resistant to radiotherapy.
Infinite proliferative potential: unlimited cell division, which leads to rapid tumor
growth.
Dormancy state: CSCs enter dormancy to evade the attack by the immune system,
awaiting new signals from the environment to re-enter the cell cycle [22].
Changes in morphology or biological function, such as the over-expression of antiapoptotic proteins that block the cell from entering the type I apoptosis cycle [1,22,24].
Elevated expression of ATP-binding cassette (ABC) pumps and detoxifying enzymes
to increase the drug’s efflux, which is considered to be an important mechanism for
multi-drug resistance (MDR). Multi-drug resistance is either intrinsic and present
before the start of treatment or acquired after exposure to treatment [25].

While the exact mechanism of CSC initiation is unclear, there are two proposed
theoretical models to explain their existence in tumor tissue:
1.

2.

The stochastic or classical model states that any somatic cell has the intrinsic ability to undergo mutation and transform into CSCs driven by genetic instability or
environmental signals, as shown in Figure 1A;
The hierarchical or cancer stem cell model states that the initiating cancer cell selfrenews in the process of cell division and forms a CSC and a normal cancer cell.
The normal cancer cell divides and generates the cells in bulk tumors, as shown in
Figure 1B [22,26].
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normal cancer cell divides and generates the cells in bulk tumors, as shown in Figure
1B [22,26].

Figure 1. Two models of cancer development: (A) the stochastic or classical model; (B) the hierarchical or cancer stem cell
model. Reprinted with permission from ref. [22], Copyright 2017 Elsevier.
Elsevier.
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targeting of cancer therapeutics [28]. Another important characteristic of CSCs is their
unique surface markers and intracellular pathways, which can be used for drug targeting.
These pathways enable CSCs to evade and survive radiation and chemotherapy and trigger
cancer relapse [3].
2.5. Surface Biomarkers
The biomarkers for CSCs vary depending on the tissue of origin, but the most wellknown CSC markers are CD44, CD90, CD133, and aldehyde dehydrogenase (ALDH), with
each marker playing a role in CSC maintenance. CD44, a common marker among many cancer types, is a transmembrane hyaluronic acid receptor involved in cell adhesion, migration,
metastasis, and drug resistance [3,18,26]. CD90 is a glycosyl phosphatidylinositol-anchored
membrane glycoprotein, which is mainly expressed in leukocytes. CD90-positive cells
possess tumorigenicity and metastatic potential [1,3]. CD133, also known as prominin-1, is
a common CSC marker in patients with a poor prognosis and resistance to conventional
therapies [3,10]. ALDH is a functional marker that is found at elevated levels in cells
associated with the CSC niche. This enzyme is responsible for CSC chemoresistance and
the detoxification of anti-cancer drugs by oxidizing aldehydes to carboxylic acids [1,10].
2.6. Signaling Pathways
CSCs use signaling pathways that are common with normal stem cells, namely, the
Hedgehog, Notch, and TGF-β pathways. These pathways regulate stemness in many
cancers [10]. Notch is an evolutionarily developmental pathway that plays an important
role in cell-fate determination and tissue development. The Hedgehog pathway is involved
in cell growth, migration, morphogenesis, and tissue maintenance and repair. TGF-β is
an important prognostic marker for various types of cancer and plays a role in the initial
phase of CSC development and self-renewal [1,3,10].
2.7. CYP Family of Enzymes
Cytochrome P450 (CYP) enzymes are involved in drug metabolism in the liver and
small intestine. Their overexpression in the tumor tissue contributes to the degradation of
anticancer drugs and multidrug resistance (MDR) [9]. The overexpression of CYP enzymes
and specific biomarkers and the activation of stemness signaling pathways are used in
targeting anticancer drugs to the CSC niche [7].
3. Polymer-Based NPs
Despite significant advances in targeted therapies, cancer patients suffer from relapse
due to drug resistance and the persistence of CSCs in the tumor tissue. While conventional
therapies are effective in eliminating bulk tumor cells, the small population of CSCs left
behind undergo an asymmetric division to form new stem cells, as well as differentiated
cells that repopulate the tumor tissue. Further, as most drugs are not specifically targeted to
cancer cells or CSCs, they suffer from serious undesired side effects [29,30]. Consequently,
there is a need to develop novel delivery systems to target cancer drugs to CSCs, the most
resistant and invasive cells in the tumor tissue. Due to their size and ability to penetrate the
dense tumor tissue, NPs serve as an attractive carrier for targeted drug delivery to tumors.
Recently, many NP types, including self-assembled polymeric NPs, inorganic NPs, natural
NPs based on proteins and exosomes, and antibody-drug conjugates, have been developed
in an attempt to target chemotherapeutic agents to surface biomarkers, biomolecules in
CSCs’ signaling pathways, or sites of overexpressed enzymes in the CSC niche. Drugloaded NPs not only protect the cargo from enzymatic degradation and diffusion away from
the target site, but they also improve the drug’s pharmacokinetics [2,10]. Aside from their
high surface to volume ratio and unique optical properties, NPs improve the bioavailability
of hydrophobic drugs in physiological media, increase drug stability, and allow for timedrelease in the target tissue [7,10]. Moreover, NPs enable the concurrent targeted delivery
of both hydrophilic and hydrophobic drugs to cells in bulk tumors, as well as to CSCs at
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a relatively high loading capacity [24,31]. The toxicity, bioavailability, and effectiveness
of drugs loaded in NPs depend to a large extent on the physiochemical and biological
properties of NPs, including the size and distribution, surface charge, hydrophilicity, drug
release rate, pharmacokinetics, and other biochemical factors [10]. There are two main
approaches to targeting chemotherapeutic agents to tumor cells using NPs:
1.

2.

Passive targeting: Pathophysiological conditions, specifically impaired angiogenesis
and a high demand for nutrients and oxygen by proliferating tumor cells, result in
an overexpression of vascular endothelial growth factor (VEGF) and the formation
of abnormal tumor vessels, with relatively large gaps between the endothelial cells’
lining lumen of the vessels. The large intercellular clefts and poor lymphatic drainage
leads to an accumulation and retention of NPs, with a size range of 100–200 nm in
the tumor tissue. This enhanced permeability and retention (EPR) effect allows for
the passive targeting of drug-loaded NPs to the tumor vasculature. However, NPs
with a short circulation time are rapidly taken up by the mononuclear phagocyte
system (MPS), prior to uptake by the tumor vasculature. Therefore, NPs should be
surface modified to prolong their residence time in circulation [32,33]. The surface
modification of NPs with non-adhesive, highly water soluble polymers, like polyethylene glycol (PEG), polyacrylic acid (PAA), and dextran, has been shown to reduce the
undesired uptake of NPs by MPS [1].
Active targeting: Antibodies or ligands that interact specifically with one or multiple
CSC surface biomarkers are used for targeting therapeutic agents to stem cells in
the tumor tissue. This approach significantly reduces drug toxicity and undesirable
uptake by normal cells [8].

Despite their many advantages as a carrier for drug targeting to CSCs, NPs are
quickly cleared from the circulation, taken up passively by pinocytosis, cause pulmonary
inflammation, translocate to other tissues, and tend to aggregate [11]. The use of drugloaded NPs surface conjugated with multifunctional antibodies and ligands targeting
concurrently to two or more biomarkers on CSCs can significantly reduce drug toxicity
and side effects while improving effectiveness [8].
3.1. PLGA NPs
Poly(lactide-co-glycolide) (PLGA) is a biodegradable polymer used in many biomedical products and is the most frequently used carrier for preparing drug-loaded NPs [10]. In
a study in nude mice with breast tumors, Yang et al. successfully used PLGA NPs, surfacemodified with lipids, for the co-delivery of paclitaxel (PTX) and curcumin (CUR) [34]. CUR
in PLGA NPs inhibited the growth of breast tumor cells by selectively targeting CSCs, while
PTX eliminated bulk tumor cells. In a mouse breast tumor model, Li et al. conjugated Salinomycin (SLM)-loaded PLGA NPs with an antibody against erbB-2 tyrosine-protein kinase
receptor (HER2) for targeting HER2-positive CSCs [35]. This approach inhibited tumor
growth and reduced the CSC subpopulation of tumor cells in vitro and in vivo. In nude
mice with ovarian tumors, PTX-loaded PLGA NPs conjugated with folic acid (FA) reduced
the expression of chemo-resistant genes ABCG2 and MDR1 and increased the expression
of apoptotic markers in tumor cells [36]. In a study with mouse CSCs with Kras mutation,
the antimicrobial agent anthothecol encapsulated in PLGA NPs inhibited the migration
and growth of pancreatic CSCs and induced apoptosis by modulating the sonic hedgehog
pathway [37]. It also inhibited colony formation by human and mouse pancreatic CSCs
in vitro. In another study in a Saos-2 osteosarcoma xenograft mouse model, SLM-loaded
PEGylated PLGA NPs, surface modified with CD133 aptamer, eliminated CD133-positive
osteosarcoma CSCs in vitro and in vivo [38]. In a study with MDA-MB-231 cells, PLGA
NPs loaded with PTX and SLM and coated with hyaluronic acid (HLA) showed a high
binding efficiency against CD44+ cells and cytotoxicity against both bulk tumor cells and
CSCs [39].
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3.2. PEG NPs
Polyethylene glycol (PEG) is widely used in medical applications to prevent protein
adsorption on biomaterials and evade the immune system [10]. In one study, pH-sensitive
PEG NPs were developed for the co-delivery of doxorubicin (DOX) and the antineoplastic
drug, SN38, to tumor cells [40]. The systemic evaluation of metabolites showed an enhanced
accumulation of the drugs in the tumor tissue through a passive EPR effect and the
elimination of both bulk tumor cells and CSCs. In another study, SLM-loaded PEGceramide nano-micelles (SCM) showed toxicity toward both bulk liver tumor cells and
CSCs [41]. In a study in a BP-474 human breast carcinoma xenograft mouse model, diblock self-assembled nano-micelles based on copolymers of PEG and acid-functionalized
polycarbonate were used for the co-delivery of DOX and thioridazine (THZ) to eradicate
bulk cancer cells and CSCs [42]. This combinational therapy is a promising approach for
treating patients with metastatic breast cancer.
3.3. PLGA-PEG Copolymer NPs
Copolymers of PLGA and PEG that self-assemble into core-shell NPs have been
used for drug delivery to CSCs. In one study, SLM-loaded PLGA-PEG NPs conjugated
with antibody against the CD133 marker were used for targeting CD133-positive ovarian
CSCs [43]. In a nude mouse model with ovarian tumor xenograft, the drug-loaded NPs
showed an enhanced bioavailability of SLM and a reduction in the fraction of CD133positive CSCs in the tumor tissue. In another study, a murine model of MDA-MB-231
orthotopic tumor was used to evaluate PLGA-block-PEG (PLGA-b-PEG) NPs loaded
with docetaxel (DTXL) and small interfering RNA (miRNA) targeting BMI-1. BMI-1 is a
member of the Polycomb repressor complex-1, which is implicated in CSC self-renewal
by mediating gene silencing and regulating the chromatin structure [44]. The bulk tumor
cells were eliminated by the release of DTXL, whereas the released miRNA downregulated
the expression of the BMI-1 oncogene in the CSCs, which reduced the expression of the
stemness markers and increased the sensitivity of CSCs to DTXL. Zhang et al. used a
combination of SLM- and gefitinib-loaded NPs, synthesized separately by an emulsionsolvent evaporation approach, to selectively eliminate CD133+ CSCs in the spheroids of
CD133+ lung cancer cells in vitro and in a xenograft mouse model inoculated with CD133+
lung tumor cells [45]. The combined delivery of SLM- and gefitinib-NPs was more effective
in eliminating CD133+ CSCs and reducing tumor volume, compared to SLM/gefitinibloaded NPs, or individually delivered SLM-NPs and gefitinib-NPs. It is possible that CSC
targeting antibodies or ligands interact with normal stem cells (NSCs) to cause undesired
cytotoxic effects, as CSCs share surface markers and signaling pathways with NSCs. In
this regard, PLGA-PEG dual-targeted NPs surface conjugated with hyaluronic acid and
doublecortin-like kinase-1 (DCLK1) monoclonal antibody against CD44 and DCLK1 cell
surface receptors, respectively, for CSC targeting were evaluated for off-target toxicity [46].
The dual-targeted NPs discriminated between CSCs and NSCs in vitro, when tested with
4T1 CSCs in an alginate-based platform and in 4T1 inoculated nude mice in vivo. In
another study, all-trans retinoic acid (ATRA)-loaded PLGA-lecithin-PEG NPs conjugated
with CD44 and CD133 antibodies were more effective in inhibiting the growth of CSCs,
compared to single-antibody-targeted NPs or non-targeted NPs [47].
3.4. Polylysine NPs
The co-delivery of hydrophilic DOX and hydrophobic CUR to brain tumors with
an optimal dose ratio is limited by differences in the pharmacokinetics (PK) and blood
brain barrier (BBB) properties of the two drugs. Xu et al. synthesized pH-sensitive coreshell polylysine-polyglutamic acid NPs for the co-delivery of DOX and CUR [48]. The
hydrophobic CUR was encapsulated in the tocopheral-grafted polylysine core, whereas
the hydrophilic DOX was encapsulated in the anionic dopamine-modified polyglutamic
acid shell deposited on the core via a pH-sensitive linkage (Figure 2).
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repair plays an important role in the self-renewal and maintenance of CSCs. The DNA
repair plays an important role in the self-renewal and maintenance of CSCs. The DNA
hypermethylation inhibitor decitabine (DAC) encapsulated in PLA-PEG NPs and combined
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bulk tumor cells and CSCs to DOX, which led to a reduction in tumor burden in breast
cancer.
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from in vivo experiments showed an increased concentration of PTX/CPY-conjugated NPs
in the tumor tissue from a passive EPR effect. Further, dual PTX/CPY-conjugated NPs
showed a higher inhibition of tumor growth, compared to PTX- or CPY-conjugated NPs.
In another work, mPEG-polycaprolactone (mPEG-PCL) NPs conjugated with an antibody
against CD133 receptors were used for the delivery of a topoisomerase inhibitor (SN-38)
to CD133-positive cells in an HCT116 xenograft mouse model [58]. The SN-38 loaded,
anti-CD133 conjugated NPs showed a higher suppression of tumor growth and reduction
of tumor size, compared to SN-38-loaded NPs without anti-CD133 or direct treatment with
irinotecan (CPT11) (Figure 4).
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3.10. ratio
Liposomes
SLM
was 1:1 for the suppression of tumor growth in a breast tumor model [61].
Liposomes are amphiphilic phospholipid vesicles used for the delivery of both hydrophilic and hydrophobic drugs [4]. A novel redox-responsive liposome was developed
for the co-delivery of SLM and DOX to liver CSCs by targeting CD133 and epithelial
cell adhesion molecule (EpCAM) receptors on the surface of CSCs [62]. According to the
experimental results, these liposomes were endocytosed by CSCs and degraded in the
cytoplasm for the rapid intercellular release of SLM and DOX to synergistically inhibit CSC
growth.
In another work, dual-targeting cationic liposomes with specificity to CD133+ glioma
stem cells were synthesized by conjugation with a low-density lipoprotein receptor-related
protein and an RNA aptamer targeting CD133 receptor on CSCs [63]. PTX and survivin
siRNA loaded in the dual-targeting liposomes induced the differentiation of glioma CSCs
and tumor cell death in a U251-CD133+ glioma xenograft mouse model. There is a need to
develop targeted therapies for patients with triple-negative breast cancer (TNBC), as the
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expressions of estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor-2 (HER2) in TNBC are downregulated. Multifunctional liposomes
(MLPs) surface-modified with chitosan, loaded with gambogic acid (GA), and labeled
with Zirconium-89 (89 Zr) have been developed for targeting CD44+ CSCs in TNBC [64].
Micro positron emission tomography (micro-PET) and Fluorescence imaging showed an
accumulation of the MLPs in the tumor tissue and uptake by cells overexpressing CD44+
marker in an MDA-MB-231 xenograft mouse tumor model. A comprehensive review of
the use of liposomes in targeting tumor cells can be found elsewhere [4].
3.11. Multi-Polymeric NPs
Polymeric biomaterials, with their wide range of properties, are extensively used in
targeted cancer therapies. A pH-sensitive PEG-benzoicimine-poly(γ-benzyl-L-aspartate)-bpoly(1-vinylimiazole) block copolymer (PPBV) was used to deliver CUR and PTX drugs to
CSCs and bulk tumor cells [65]. A unique feature of PPBV is its ability to switch its surface
charge from neutral to positive, de-shield its PEG layer, and reduce its size to penetrate
deep into the tumor tissue. In another study, thermally-responsive and pH-sensitive NPs
based on Pluronic F127, PLGA, and chitosan coated with hyaluronic acid (HA) were used
to target DOX and irinotecan (Camptosar or CPT) drugs to bulk tumor cells and CSCs in a
prostate xenograft mouse model [66]. The HA coating of the NPs was used to target the
drugs to CSCs in the prostate tumor tissue. The HA coating replaced polyvinyl alcohol
(PVA) as a stabilizer in the double emulsion method used to form the NPs. Based on the
in vitro and in vivo results, the DOX and CPT loaded NPs synergistically reduced the drug
resistance of CSCs in the prostate tumor tissue.
3.12. Other Polymeric NPs
Cationic albumin NPs loaded with ATRA and functionalized with HA have been
developed for targeting the CD44 receptor in CSCs [67]. In vivo imaging in a mouse model
showed an accumulation of the NPs in a tumor-bearing lung and the suppression of tumor
growth. Photodynamic therapy (PDT) generates cytotoxic singlet reactive oxygen species
(ROS) in tumor tissue by transferring energy from a photosensitizer to the surrounding
oxygen molecules. However, this approach is limited by the low levels of oxygen in the
hypoxic environment of tumors. NPs based on sodium alginate and docusate loaded with a
photosensitizer-like methylene blue have been used to overcome this limitation of PDT [68].
The experimental results with the methylene blue-loaded NPs demonstrated that the extent
of ROS generation depended on the interaction of the cationic photosensitizer with the
anionic alginate. The methylene blue-loaded NPs eliminated the CSCs in MCF7 tumor cells
treated with PDT. In another work, Dox-loaded Pluronic F127 NPs surface-modified with
chitosan were used as a pH-sensitive carrier for targeting CSCs [69]. The role of chitosan
was to target the NPs to CD44+ cells and release the drug in the slightly acidic environment
of the tumor. The results showed a 6-fold increase in the tumor toxicity of DOX-loaded,
pH-sensitive, and CD44+ -targeting NPs, as compared to free DOX. In another study, silk
fibroin nanogels, formed by an aqueous process, were used as a carrier for targeting
SLM and PTX to CSCs and bulk tumor cells in a hepatic tumor mouse model [70]. The
nanogel carrier showed effectiveness against bulk tumor cells and CSCs in vivo. In another
study, the addition of N,N-Dimethylhexylamine (DMHA) and α-tocopheral additives
to immune-tolerant, elastic-like polypeptide (iTEP) NPs loaded with SLM improved the
loading efficiency and half-life of the NPs in circulation by 4-fold [71]. Further, the additives
increased the area-under-curve (AUC) for SLM in the plasma by ten times, which increased
the accumulation of SLM in the tumor tissue and enhanced the elimination of CSCs in a
4T1 orthotopic tumor model.
Polymeric NPs represent an ideal platform for targeted drug delivery to CSCs because
of their biodegradability, biocompatibility, and storage stability. However, the particle
aggregation and toxicity can be limiting factors in the long term. As a result, only a few
polymeric NPs have been approved by the FDA for clinical use [72].
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4. Inorganic NPs
Inorganic NPs, with sizes as low as a few nanometers and a uniform distribution,
are very attractive as passive or active carriers in tumor targeting [73]. However, their
use is limited by their rapid clearance from circulation through the reticuloendothelial
system (RES), as well as their rapid recognition and elimination by scavenger receptors
on Kupffer cells in the liver [74,75]. These limitations can be overcome by tailoring their
physicochemical properties, such as particle shape, size, and surface chemistry, to a specific
cancer therapy application. It should be noted that each type of inorganic nanomaterial
possesses its own unique properties, which determine its interaction with cells, particularly
with respect to cell uptake.
4.1. Gold NPs
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Due to their biocompatibility, nontoxicity, and narrow size distribution, bare and
surface-modified gold (Au) NPs have received considerable attention as passive or active
drug carriers in cancer therapy [26,76]. The surface modification of Au NPs via ligand
immobilization approaches improved their in vivo performance as a carrier for targeted
tumor drug delivery [77]. Further, the surface functionalization of Au NPs with biocompatible coatings has improved their biocompatibility in physiological media. In one study,
bare Au NPs were synthesized by sodium citrate reduction, followed by coating with
thiol-terminated PEG, to form NPs with an average size of 20 nm [78]. PEGylation not only
reduced the aggregation of Au NPs, but it also increased their stability and biocompatibility.
The conjugation of SLM to PEGylated Au NPs improved the drug uptake by breast CSCs
expressing CD24− /CD44+ markers and enhanced drug-induced tumor cell death. As
cancer cells have a higher consumption of glucose (Glu) than healthy cells, Glu could
potentially be used as a reagent in tumor targeting [79]. Recently, a two-step bottom-up
approach was used to synthesize Glu Au NPs with an average size of <50 nm, as shown
in Figure 5 [80]. In the first step, a Glu-functionalized PEG-block-cationomer was neutralized with a single pair of siRNAs by charge-matching to form unimer polyion complexes
(uPICs). Next, the synthesized uPICs were immobilized on the surface of Au NPs by
Au-S coordination between the AU surface and thiol groups of Glu to form monodisperse
Glu-Au NPs. The Glu moieties on the surface of Au NPs led to their recognition by glucose
transporter-1 (GLUT1) overexpressed on the surface of CSCs. The Glu functionalized
Au NPs improved the antitumor activity toward GLUT1-overexpressing MDA-MB-231
spheroids and MDA-MB-231 orthotropic tumors. The same group previously reported the
of 25 to solid
synthesis of two other uPIC-Au NPs as a carrier for the systemic delivery of12siRNA
tumors [81,82].
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Au NPs have also been functionalized with folic acid, transferrin, and bombesin peptides for targeted drug delivery to ovarian, prostate, and breast cancers, respectively [83–
85]. Latorre et al. synthesized albumin-stabilized Au NPs by incubating gold salt with
bovine serum albumin (BSA) in a basic medium, followed by the conjugation of DOX and
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Su et al. synthesized super-magnetic Fe3 O4 NPs (SPIONPs) using a coprecipitation
method in the presence of Fe2+ and Fe3+ in a basic medium [88]. Following the synthesis,
the surface of SPIONPs were functionalized with carboxyl groups by a reaction with
carboxymethyl dextran. The surface carboxyl groups were then used to covalently link
a the CD44 antibody to SPIONPs via 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) chemistry by a reaction with the amine groups of the antibody. The magnetic
fluid hyperthermia generated by the anti-CD44-functionalized SPIONPs in an alternating
magnetic fluid (AMF) appreciably reduced the CSC subpopulation of tumor cells in a
head and neck squamous cell carcinoma model. IONPs with multiple targeting modalities
enable the binding of the NPs to multiple receptors on the surface of the CSCs in tumor
cells. In this regard, ultra-small IONPs with an average size of 5 nm, surface-modified with
two peptides targeting Wnt/LRP5-6 and the urokinase plasminogen activator receptor
(uPAR), downregulated Wnt/β-catenin signaling and marker expression of CSCs, resulting
in a greater inhibition of tumor growth in a patient-derived xenograft (PDX) breast tumor
model, as compared to single-targeting IONPs [89].
4.3. Silica NPs
The use of silica NPs in drug and gene delivery has been growing in the last decade [90].
Mesoporous silica (MS) NPs as a drug carrier possess unique properties, including a tunable
size, large surface area and porosity, ease of functionalization, and an ordered porous
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structure for drug delivery to CSCs [91]. Surface-functionalized MS NPs with defined
shape and controlled pore size have been synthesized to efficiently deliver hydrophobic
anticancer drugs and nucleic acids to tumors. Recently, a pH-responsive carrier was
developed based on MS NPs conjugated with dendritic polyglycerol (dPG) for the codelivery of DOX and tariquidar (TAR) to the CSC subpopulation of breast cancer cells [92].
The DOX- and TAR-loaded MS NPs suppressed the expression of CSC-associated markers
and blocked spheroid formation in a breast MDA-MB-231 spheroid model. In another
work, MS NPs modified with cationic polyethyleneimine (PEI) were used as a dual-targeted
carrier for the delivery of HNF4α-encoding plasmid and cisplatin to CSCs in hepatocytederived Huh7 carcinoma cells [93]. Based on the experimental results, the load MS NPs
blocked the division of Huh7 cells in the S-phase of the cell cycle, leading to apoptosis.
Due to their magnetic, radioactive, and plasmonic properties, inorganic NPs are used
clinically in diagnostic and imaging applications, as well as photothermal therapies. While
most inorganic NPs possess a good biocompatibility and stability, their clinical applications
are somewhat limited by their toxicity and low degradability in physiological media [72].
5. Self-Assembling Protein NPs
Conventional approaches to cancer treatment are limited by undesired toxic side
effects and a lack of control over the local drug concentration in the tumor tissue, which
has led researchers to explore alternative solutions. While nanocarriers improve the drug
biodistribution and passive and active targeting, reduce renal clearance, protect the drug
from degradation, and enhance cell uptake, only a fraction of the administered drug reaches
the tumor tissue. Further, the persistence of the carrier in the tumor and healthy tissues
leads to undesired toxic effects [94,95]. NPs based on multifunctional proteins that are degraded by natural enzymatic pathways are attractive as a carrier for passive or active drug
targeting to tumors [96]. CXCR4 is a viable target in cancer therapy, because it mediates
cancer metastasis by inducing the migration of tumor-associated cells. A single-chain variable fragment (scFv) antibody targeting CXCR4 was fused with an RNA-binding protein
peptide (RBM) and mixed with miR-127-5p, a mediator of M1 macrophage polarization, to
form self-assembling RNA-protein nanoplexes [97]. These nanoplexes served as a carrier
for targeting miRNA to tumor-associated cells that express CXCR4. In a 4T1 TNBC mouse
model, these nanoplexes inhibited the migration of tumor-associated cells, polarized the
macrophages to the M1 phenotype, and suppressed tumor growth [97]. In another study, a
modular fusion protein composed of an N-terminal cationic peptide T22-targeting CXCR4
receptor on tumor cells and a C-terminal polyhistidine tag (H6) on a fluorescent GFP
protein scaffold for imaging was used to form self-assembled NPs for tumor targeting [98].
The peptide T22 and polyhistidine tag H6 induced the self-assembly of the modular protein
into fluorescent NPs with an average size of 12 nm. The T22 peptide facilitated the binding
and internalization of the NPs in CXCR4+ tumor cells for targeted intracellular drug delivery. In a recent study, the drugs, oligo-floxuridine (FdU) and monomethyl auristatine
E (MMAE), were chemically coupled to exotoxin A from Pseudomonase aeruginosa and
diphtheria toxin from Corynebacterium diphtheria, respectively, to form self-assembled
protein NPs with an average size of 50 nm targeting CXCR4+ tumor cells [95]. Based on
in vitro studies, the resulting protein NPs were internalized by CXCR4+ cells and inhibited
the growth of tumor cells. Ribosome-inactivating proteins (RIPs) are considered potent
therapeutic agents for cancer therapy, as they inactivate ribosomes in cancer cells and
inhibit protein synthesis, leading to cell death. In this regard, magnetic NPs were surface
modified with a fusion protein composed of the small protein, Barstar (Bs), synthesized by
Bacillus amyloliquefaciens, which inhibits bacterial ribonuclease and the C-terminal part
of the magnetite binding protein of magnetotactic bacteria (Mms6) [99]. These Bs-C-Mms6
magnetic NPs undergo a spontaneous self-assembly with a Barnase-containing biomolecule
by a specific Barstar-Barnase interaction for targeted drug delivery. As a proof of concept, a
fusion protein of Barnase and the peptide DARPin9.29 that binds to the HER2/neu receptor
underwent a self-assembly with Bs-C-Mms6 NPs to target magnetic particles to HER2/neu
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overexpressed cells in breast cancer tissue [99]. Gelonin is a ribosome-inactivating protein
(RIP) used in cancer therapy to block the growth of cancer cells. In one study, gelonin was
conjugated to monocrystalline nickel-iron oxide (NiFe2 O4 ) NPs (MIONs) using a multifunctional peptide linker for targeted delivery to tumor cells in a fibrosarcoma xenograft mouse
model [100]. The multifunctional peptide consisted of a 6-mer histidine tag (6His-Tag) for
attachment to the MION followed by a matrix metalloproteinase-2 (MMP-2) degradable
sequence and a low-molecular-weight peptide (LMWP) for cell penetration. Following
uptake, the MMP-2 degradable peptide is degraded by overexpressed MMP-2 in the tumor
tissue, resulting in the release of gelonin-LMWP and endocytosis by the tumor cells, facilitated by the cell penetrating peptide. The in vivo results showed an enhanced cytotoxicity
of the MIONs against the tumor cells in a fibrosarcoma xenograft mouse model [100]. These
studies indicate that protein NPs, due to their biodegradability and tunable self-assembly,
are especially useful for the delivery of amino acid-based bioactive agents, such as RIPs
and antibodies.
Naturally occurring or synthetic amino acid sequences used in assembling protein
NPs can be immunogenic. The immune response can neutralize the drug’s effectiveness or
cause serious side effects in therapeutic applications. In some cases, these peptides can be
immunosuppressive, and their long-term administration can cause severe side effects, such
as relapsed bacterial, viral, or fungal infections [101]. The targeting agent in the delivery of
cytotoxic proteins should have a high selectivity for receptors on tumor-associated cells to
reduce the risk of serious side effects in healthy tissues [102].
6. Antibody Drug Conjugates
An exciting approach to the targeted delivery of drugs in cancer therapy is the use
of antibody-drug conjugates (ADC), which was named as the “magic bullet” by Paul
Ehrlich [103]. He proposed the use of an antibody against tumor cells conjugated to the
diphtheria toxin for cancer therapy. ADCs are drugs designed to target specific receptors
on tumor cells, CSCs, or tumor-associated cells for localized intracellular delivery [104,105].
An ADC consists of a drug bound to an antibody by conjugation via a special protein,
called the linker protein (Figure 7). After binding to a surface receptor on CSCs, ADC is
engulfed by the CSC, and the drug is released from the conjugate to eliminate the cell [104].
The most important factor in the design of an ADC is the selection of a target antigen
that binds with a high specificity to the antibody to minimize off-target toxic side effects
to healthy cells. The number and density of target antigen molecules on the surface of
CSCs affect the extent of the ADC engulfment by tumor cells. Further, antigen secretion
by the CSCs to the circulation should be minimal to limit the circulatory detection of the
ADC-antigen and activation of the immune system. Table 1 summarizes the list of surface
antigens on tumor cells used in designing antibody-drug conjugates for different types of
cancers [104,106].
Another factor is the selection of an antibody to target the antigens on the surface
of CSCs with a high specificity, strong binding affinity, and long circulation half-life for
prolonged uptake and retention by the tumor tissue. The efficient internalization by CSCs
and low immunogenicity of the ADC are important factors in the selection process [106,107].
The pharmacokinetics and pharmacodynamics of ADC is affected by the choice of linker
that connects the antibody to the drug molecule. The linker should stabilize the ADC
in circulation but provide a mechanism for the release of the payload when the ADC
reaches the tumor site. Linkers are divided into non-cleavable and cleavable linkers [108].
Non-cleavable linkers form stable bonds with antibodies and have a longer half-life in
circulation. Further, after internalization, non-cleavable linkers should degrade in the
lysozyme to release the drug molecule inside the targeted tumor cell. The stability of
cleavable linkers depends on the physiological conditions in the tumor tissue and the
expression of enzymes for cleavage of the linker to release the drug in the tumor site. The
tumor toxicity of the ADC depends on the choice of payload (drug molecule) attached
to the antibody. Conventional cancer drugs, such as DOX or mitomycin, have been used
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PDX tumor model with a low HER2 expression, in which T-DM1 was not effective [112].
The RON tyrosine kinase receptor on macrophage-stimulating proteins (MSP) and its PSI
domain, which facilitates the proper positioning of RON for ligand-receptor binding, are
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implicated in tumor progression in TNBC [113]. In one study, antineoplastic monomethyl
auristatin E and duocarmycin DNA-alkylating agents were conjugated to the humanized
antibody against the RON PSI domain as an anti-RON ADC [114]. The ADC inhibited the
spheroid formation and eliminated the CSCs with the RON+ /CD44+ /ESA+ phenotype. A
single injection of the ADC inhibited the tumor growth in multiple xenograft tumor models,
including LoVo colorectal, H358 non-small cell lung, HT-29 colon, L36.pl pancreatic, and
T-47D breast cancers, as shown in Figure 8 [114].
Table 1. Target antigens for ADCs under development or in the clinic for cancer therapy [106].
Indication

Targets

Acute myeloid leukaemia

CD25, CD33, CD123 (IL-3Rα), FLT3

Breast cancer

CD25, CD174, CD197 (CCR7), CD205 (Ly75), CD228 (P79,
SEMF), c-MET, CRIPTO, ErbB2 (HER2), ErbB3 (HER3),
FLOR1 (FRα), Globo H, GPNMB, IGF-1R, integrin β-6, PTK7
(CCK4), nectin-4 (PVRL4), ROR2, SLC39A6 (LIV1A ZIP6)

Bladder cancer

CD25, CD205(Ly75)

Colorectal cancer

CD74, CD174, CD166, CD227 (MUC-1), CD326 (Epcam),
CEACAM5, CRIPTO, FAP, ED-B, ErbB3 (HER3)

Gastric cancer

CD25, CD197 (CCR7), CD228 (P79, SEMF), FLOR1(FRα),
Globo H, GRP20, GCC, SLC39A6 (LIV1A ZIP6)

Gliomas GIII and GIV

CD25, EGFR

Head and neck cancer

CD71 (transferrin R), CD197 (CCR7), EGFR, SLC39A6
(LIV1A ZIP6)

Hodgkin’s lymphoma

CD25, CD30, CD197 (CCR7)

Lung cancer

Axl, alpha v beta6, CD25, CD56, CD71 (transferrin R),
CD228 (P79, SEMF), CD326, CRIPTO, EGFR, ErbB3 (HER3),
FAP, Globo H, GD2, IGF-1R, integrin β-6, mesothelin, PTK7
(CCK4), ROR2, SLC34A2 (NaPi2b), SLC39A6 (LIV1A ZIP6)

Liver cancer

CD276 (B7-H3), c-MET

Melanoma

CD276 (B7-H3), GD2, GPNMB, ED-B, PMEL 17, endothelin
B receptor

Mesothelioma

Mesothelin, CD228 (P79, SEMF)

Multiple Myeloma

CD38, CD46 (MCP), CD56, CD74, CD138, CD269 (BCMA),
endothelin B receptor

Non-Hodgkin Lymphoma

CD19, CD20, CD22, CD25, CD30, CD37, CD70, CD71
(transferrin R), CD72, CD79, CD180, CD205 (Ly75), ROR1

Ovarian cancer

CA125(MUC16), CD142 (TF), CD205 (Ly75), FLOR1(FRα),
Globo H, mesothelin, PTK7 (CCK4)

Pancreatic cancer

CD25, CD71 (transferrin R), CD74, CD227 (MUC1), CD228
(P79, SEMF), GRP20, GCC, IGF-1R, integrin β-6, nectin-4
(PVRL4), SLC34A2 (NaPi2b), SLC44A4, alpha v beta6,
mesothelin

Prostate cancer

CD46 (MCP), PSMA, STEAP-1, SLC44A4, TENB2

Renal cancer

AGS-16, EGFR, c-MET, CAIX, CD70, FLOR1 (FRα)
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One of the challenges in designing ADCs for clinical applications is the stability of
the linker. ADCs can circulate in the bloodstream for a significant amount of time, before
reaching their target tissue. Therefore, the linker should have a sufficient stability to
prevent the premature release of the cytotoxic agent in circulation [103]. This is a serious
concern, because most cancer drugs used with ADCs are highly toxic in their free form.
As a result, the premature release of the drug in circulation can cause serious side effects,
such as low red and white cell counts, low platelet count, damage to the liver, peripheral
neuropathy, and vision problems [104]. Conversely, a proper linker selection in ADCs
ensures the targeted delivery of cytotoxic drugs to CSCs in the tumor tissue with a high
selectivity [107].
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7. Extracellular Vesicles
Extracellular vesicles (EVs) are lipid bilayer NPs exocytosed by cells for the intercellular transport of biomolecules and cell signaling. The diameter of EVs is in the range
of 30–2000 nm, and these vesicles contain proteins, nucleic acids, lipids, and sugars. In
cancer, EVs contribute to tumor progression by transporting and sharing biomolecules that
enhance tumor growth or resist therapy between cancer cells [119]. Exosomes are formed in
the cytoplasm and have a diameter of 30–150 nm, whereas microvesicles are formed by the
outward expansion and fission of the cell membrane and have a diameter of 200–2000 nm.
Apoptotic bodies, which are the largest EVs with a diameter of 500–2000 nm, are released
during apoptosis and contain a cell nucleus, organelles, and proteins from the apoptotic
cell [120]. In cancer, EVs have attracted interest for reversing tumor progression, because
they facilitate cell–cell communication and maintenance and elicit a constructive, as opposed to inflammatory, immune response by acting as antigen-presenting vesicles [121].
EVs exchange information between CSCs and other tumor cells in the form of functional
proteins, mRNAs, miRNAs, and small DNA fragments that contribute to tumor growth
and progression. Cancer cells release more exosomes than other cell types to regulate the
metabolism of the recipient cells, reprogram the cells to undergo apoptosis, mitosis, or angiogenesis, suppress the response of immune cells, or transfer oncogenic factors. Exosomes
released by CSCs could transport stemness-associated factors or drug-resistant factors to
the recipient cells [119]. Exosomes, due to their biocompatibility, low immunogenicity, long
circulation time, and high loading capacity have been used as a nano-carrier in drug and
gene delivery [122]. Further, the uptake of exosomes by tumor cells is >10-fold higher than
that of liposomes, with a higher specificity of exosomes to tumor-associated cells [123].
Other EV types, such as microvesicles and apoptotic bodies, have a limited use in cancer
therapy because of their large size and limited ability to penetrate the tumor tissue.
Exosomes can be engineered to target CSCs in cancer therapy. Autophagy is an intracellular process for the clearance, degradation, exocytosis of damaged organelles and cell
components, or the ejection of foreign bodies [124]. In one study, luminescent porous silicon
NPs (PsiNPs) with an average diameter of 150 nm, generated by electrochemical etching,
were loaded with DOX [125]. Next, the DOX-PSiNPs were incubated with human hepatocarcinoma cells to undergo endocytosis (Figure 9). The experimental results showed that
the endocytosed PSiNPs were localized to multivesicular bodies (MVBs) and induced the
formation of autophagosomes, which led to autophagy. Following washing and incubating
the cells with a fresh medium, the endocytosed DOX-PSiNPs fused with the cell membrane
and exocytosed to the extracellular space as exosome-sheathed DOX-PSiNPs. The treatment
of subcutaneous, orthotopic or metastatic tumors with exosome-sheathed DOX-PSiNPs
resulted in an enhanced tumor penetration, cellular uptake, DOX accumulation in CSCs,
and elimination of CSCs [125].
It has been reported that exosomes carry and translocate membrane proteins from tumor cells in one organ to healthy cells in other organs to serve as seed surface receptors for
the landing and proliferation of migrated cancer cells [126]. The membrane protein, p120Catenin (p120ctn), is downregulated in exosomes exocytosed by hepatocellular carcinoma
cells (HCCs), as compared to exosomes exocytosed by healthy liver cells [127], implying that
the downregulation of p120ctn simulates tumor growth and progression. HCCs treated
with exosomes isolated from hepatoma cells transfected with p120ctn-overexpressing
lentivirus formed fewer colonies and inhibited the proliferation and migration of HCCs.
Further, the p120-ctn overexpressing exosomes reduced tumor growth in a hepatocarcinoma xenograft mouse model [127]. The expression of miR-21-5p was upregulated in
the EVs isolated from M2-polarized tumor-associated macrophages [128]. The miR-21-5p
upregulated exosomes derived from M2 polarized macrophages enhanced the proliferation
and activity of pancreatic CSCs [129]. Further, the downregulation of miR-21-5p in EVs
isolated from M2 polarized macrophages inhibited colony formation by pancreatic CSCs
in vitro and tumor growth in vivo in an exosome-incubated pancreatic CSC xenograft
mouse model [129].
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for targeting and uptake by CSCs. Inorganic NPs based on gold, iron oxide, and silica
have been used as carriers for drug targeting to CSCs, as well as imaging. Multifunctional
protein NPs, due to their degradability by natural enzymes, tunable self-assembly, and
natural ability to penetrate the cell membrane, are attractive in connection with the delivery
of amino-acid-based therapeutic agents, such as ribosome-inactivating proteins (RIP), to
inhibit protein synthesis and cell growth in cancer cells. ADCs are highly effective in
eliminating metastatic and recurrent cancers with the selection of antibodies with a high
specificity against CSC surface receptors, an appropriate choice of therapeutic agents, and
the proper selection of enzymatically degradable linkers for intracellular drug delivery to
CSCs. Exosomes and other EVs, due to their low immunogenicity, long circulation time, and
high loading capacity, are very attractive as a carrier for the delivery of functional proteins,
mRNAs, miRNAs, and small DNA fragments to CSCs for reversing tumor progression,
because EVs facilitate cell–cell communication by acting as antigen-presenting vesicles.
Drug-loaded polymeric, inorganic or protein NPs, ADCs, and EVs that selectively interact
with multiple surface receptors’ tumor-associated stem cells provide the prospect of an
enhanced drug bioavailability and uptake in tumor tissue, with fewer undesired side effects
in healthy tissue, thus improving the quality of life of cancer patients.
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